Výsledky vyhledávání - "Gilles Paintaud"

Akademický článek

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases

Autor: Eurydice Angeli, Justine Paris, Olivier Le Tilly, Céline Desvignes, Guillaume Gapihan, Didier Boquet, Frédéric Pamoukdjian, Diaddin Hamdan, Marthe Rigal, Florence Poirier, Didier Lutomski, Feriel Azibani, Alexandre Mebazaa, Amaury Herbet, Aloïse Mabondzo, Géraldine Falgarone, Anne Janin, Gilles Paintaud, Guilhem Bousquet

Publikováno v: Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)

Abstract Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the lim

Externí odkaz: https://doaj.org/article/e86f2a9c1410412ea0b96fb01811d5ae

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

Autor: Cristina Bagacean, Adrian Tempescul, David Ternant, Anne Banet, Nathalie Douet-Guilbert, Anne Bordron, Boutahar Bendaoud, Hussam Saad, Mihnea Zdrenghea, Christian Berthou, Gilles Paintaud, Yves Renaudineau

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)

Abstract Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemot

Externí odkaz: https://doaj.org/article/874ce61e568a46c38d593ea120b275c2

Zobrazit plný text záznamu

Akademický článek

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

Publikováno v: EClinicalMedicine, Vol 28, Iss , Pp 100566- (2020)

Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bev

Externí odkaz: https://doaj.org/article/e12828e210e34b18a595bb3ec526544b

Zobrazit plný text záznamu

Akademický článek

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

Publikováno v: RMD Open, Vol 6, Iss 1 (2020)

Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.Methods A total of 110 patients eligi

Externí odkaz: https://doaj.org/article/34baabbabbb84c789d1f58a0aed02800

Zobrazit plný text záznamu

Akademický článek

Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX)

Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)

Anti-epidermal growth factor receptor (EGFR) monoclonal antibody is a standard treatment of metastatic colorectal cancer (mCRC) and its most common adverse effect is a papulopustular acneiform rash. The aim of the CUTACETUX study was to characterize

Externí odkaz: https://doaj.org/article/67460d410cf341d2befbf14fffd4f28a

Zobrazit plný text záznamu

Akademický článek

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

Autor: David Ternant, Olivier Le Tilly, Laurence Picon, Driffa Moussata, Christophe Passot, Theodora Bejan-Angoulvant, Céline Desvignes, Denis Mulleman, Philippe Goupille, Gilles Paintaud

Publikováno v: Pharmaceutics, Vol 13, Iss 11, p 1821 (2021)

Infliximab is an anti-TNF-α monoclonal antibody approved in chronic inflammatory bowel diseases (IBD). This study aimed at providing an in-depth description of infliximab target-mediated pharmacokinetics in 133 IBD patients treated with 5 mg/kg infl

Externí odkaz: https://doaj.org/article/e2d78037197449f6a4091c5a92ae7319

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

Autor: Emilie Lereclus, Mira Tout, Alban Girault, Nadine Baroukh, Morgane Caulet, Christophe Borg, Olivier Bouché, David Ternant, Gilles Paintaud, Thierry Lecomte, William Raoul

Publikováno v: BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)

Abstract Background Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial

Externí odkaz: https://doaj.org/article/a8c37056c41044d689e6b839974df1b8

Zobrazit plný text záznamu

Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition model

Autor: Olivier Le Tilly, Philippe Gatault, Christophe Baron, Theodora Bejan‐Angoulvant, Matthias Büchler, Gilles Paintaud, David Ternant

Publikováno v: British Journal of Clinical Pharmacology. 88:3500-3505

Basiliximab, an anti-CD25 chimeric monoclonal antibody, is approved in prevention of acute kidney transplant rejection. This study aims at investigating target-mediated pharmacokinetics of basiliximab.Data from the IDEALE study, where 16 kidney trans

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae8146d2c34f0848e0ed8a12e2eaa0d
https://doi.org/10.1111/bcp.15235

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání